HLA-haploidentical blood progenitor cell transplantation in osteopetrosis.

Infantile osteopetrosis (OP) carries an extremely poor prognosis unless treated early by hematopoietic stem cell transplantation. We explored the use of purified blood progenitor cells from HLA-haploidentical parents in 7 patients lacking suitable matched donors. Blood progenitor cells were purified by positive selection and by additional T-cell depletion using rosette formation. For conditioning, patients received busulfan, thiotepa, and either cyclophosphamide (5 patients) or fludarabine (2 patients). Stable donor engraftment developed in 6 of 7 patients. Graft-versus-host disease was not observed. Three of the 7 patients had no major complications and 4 of 7 had both veno-occlusive disease and respiratory failure. Five of 7 patients survive with complete cure of OP at a median of 4 years. Patients with OP lacking HLA-matched donors can be successfully treated by transplantation of purified blood progenitor cells from HLA-haploidentical donors.

[1]  W. Friedrich,et al.  Severe combined immunodeficiency: treatment by bone marrow transplantation in 15 infants using HLA-haploidentical donors , 1985, European Journal of Pediatrics.

[2]  A. Schulz,et al.  Loss of the ClC-7 Chloride Channel Leads to Osteopetrosis in Mice and Man , 2001, Cell.

[3]  A. Schulz,et al.  Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis. , 2000, Human molecular genetics.

[4]  L. Notarangelo,et al.  Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis , 2000, Nature Genetics.

[5]  A. Fasth,et al.  Human malignant osteopetrosis: Pathophysiology, management and the role of bone marrow transplantation , 1999, Pediatric transplantation.

[6]  K. Schwarz,et al.  Definition of a critical T cell threshold for prevention of GVHD after HLA non-identical PBPC transplantation in children , 1999, Bone Marrow Transplantation.

[7]  M. Martelli,et al.  Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Martelli,et al.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. , 1998, The New England journal of medicine.

[9]  W. Friedrich,et al.  Combined CD34 positive plus CD2 negative selection for effective T-cell depletion as GvHD-prophylaxis in HLA-nonidentical blood progenitor cell transplantation. , 1996, Transfusion science.

[10]  M. Cecchini,et al.  Recent developments in the understanding of the pathophysiology of osteopetrosis. , 1996, European journal of endocrinology.

[11]  W. Friedrich,et al.  Bone marrow transplantation for autosomal recessive osteopetrosis. A report from the Working Party on Inborn Errors of the European Bone Marrow Transplantation Group. , 1994, The Journal of pediatrics.

[12]  A. Fischer,et al.  European experience of bone-marrow transplantation for severe combined immunodeficiency , 1990, The Lancet.

[13]  K. Sullivan,et al.  Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. , 1989, The New England journal of medicine.

[14]  B. Dupont,et al.  Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. , 1983, Blood.

[15]  S. Teitelbaum,et al.  Successful bone-marrow transplantation for infantile malignant osteopetrosis. , 1980, The New England journal of medicine.

[16]  John P. Mettauer,et al.  Amputation of the Penis , 1837 .